JAKAVI demonstrated comprehensive haematologic control1,2
Significantly more patients receiving JAKAVI achieved complete haematologic remission (CHR) compared with those in the BAT arm1,2
- JAKAVI enabled more than twice as many patients to achieve CHR1,2
CHR at Week 321-3
CHR was defined as having achieved all of the following: haematocrit control, platelet count ≤400 x 109/L, and leukocyte count ≤10 x 109/L.1
- CHR was a key secondary endpoint1
88.5% of patients who achieved CHR at Week 32 maintained CHR at Week 484
• Durability of CHR at Week 48 was a secondary endpoint3
JAKAVI helped control multiple key blood counts1-3
Control rates of key haematologic parameters at Week 321-3
Haematocrit control was defined as the absence of phlebotomy eligibility, with no more than one post-randomisation phlebotomy allowed prior to Week 8. Phlebotomy eligibility was defined as haematocrit >45% and ≥3% higher than baseline or >48%, whichever was lower.1,2 Leukocyte control and platelet control as components of CHR were defined as ≤10 x 109/L and ≤400 x 109/L, respectively.1
- The measures shown are the individual components of CHR, which was a key secondary endpoint1
